RxDoctor Payments Data

Jesus Leandro Almendral, MD

Cardiovascular Disease · New Brunswick, NJNPI 1346408689

Payments from drug & device makers

$75,767in general payments, 2019–2025

Across 253 payments — averaging $299.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$42K
  • Procyrion, Inc.$20K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8K
  • Abbott$2K
  • AstraZeneca$530
  • Cvrx, Inc.$338
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$5,13892%
  • Education$4658%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,767 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$163,025
Medicare patients
179
Services billed
1,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis13$410,329
EntrestoSacubitril/Valsartan156$185,260
JardianceEmpagliflozin78$84,005
FarxigaDapagliflozin Propanediol34$40,143
VerquvoVericiguat19$13,406
Sildenafil Citrate14$4,446
Bumetanide93$4,040
Tacrolimus13$3,531
Metoprolol Succinate76$2,142
Eplerenone26$2,020
Carvedilol106$999
Torsemide21$997
Potassium Chloride34$970
Spironolactone92$668
Valsartan20$623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax$255$410,32913 claims
NovartisEntresto$205$185,260156 claims
Boehringer IngelheimJardiance$170$84,00578 claims
AstraZenecaFarxiga$530$40,14334 claims
MerckVerquvo$305$13,40619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →